TCIM
LXRX icon

TIAA CREF Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

TIAA CREF Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$473K Sell
85,036
-52,231
-38% -$317K ﹤0.01% 2620
2018
Q4 		$911K Sell
137,267
-26,100
-16% -$211K ﹤0.01% 2322
2018
Q3 		$1.74M Buy
163,367
+28,355
+21% +$325K ﹤0.01% 2192
2018
Q2 		$1.62M Buy
135,012
+34,636
+35% +$354K ﹤0.01% 2284
2018
Q1 		$860K Hold
100,376
– – ﹤0.01% 2511
2017
Q4 		$992K Sell
100,376
-16,025
-14% -$167K ﹤0.01% 2466
2017
Q3 		$1.43M Buy
116,401
+1,041
+0.9% +$15.4K ﹤0.01% 2340
2017
Q2 		$1.9M Sell
115,360
-38,623
-25% -$598K ﹤0.01% 2213
2017
Q1 		$2.21M Sell
153,983
-70,665
-31% -$1.05M ﹤0.01% 2085
2016
Q4 		$3.11M Sell
224,648
-69,950
-24% -$1.12M ﹤0.01% 1930
2016
Q3 		$5.32M Buy
294,598
+82,171
+39% +$1.32M ﹤0.01% 1565
2016
Q2 		$3.05M Buy
212,427
+59,653
+39% +$809K ﹤0.01% 1865
2016
Q1 		$1.83M Sell
152,774
-10,030
-6% -$105K ﹤0.01% 2122
2015
Q4 		$2.17M Sell
162,804
-24,984
-13% -$307K ﹤0.01% 2093
2015
Q3 		$2.02M Buy
187,788
+45,996
+32% +$502K ﹤0.01% 2133
2015
Q2 		$1.14M Buy
141,792
+19,563
+16% +$144K ﹤0.01% 2629
2015
Q1 		$808K Hold
122,229
– – ﹤0.01% 2733
2014
Q4 		$779K Sell
122,229
-1,942
-2% -$15.7K ﹤0.01% 2795
2014
Q3 		$1.23M Sell
124,171
-2,019
-2% -$21.6K ﹤0.01% 2523
2014
Q2 		$1.42M Sell
126,190
-3,165
-2% -$34K ﹤0.01% 2504
2014
Q1 		$1.57M Sell
129,355
-2,845
-2% -$36.4K ﹤0.01% 2377
2013
Q4 		$1.67M Hold
132,200
– – ﹤0.01% 2356
2013
Q3 		$2.19M Sell
132,200
-1,910
-1% -$32K ﹤0.01% 2142
2013
Q2 		$2.04M Buy
+134,110
New +$2.04M ﹤0.01% 2151

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TIAA CREF Investment Management's LXRX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 38% in Q1 2019, selling an estimated $317K and leaving 85,036 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

TIAA CREF Investment Management first reported a position in LXRX in Q2 2013 and has held it in 24 quarters since. The position peaked at $5.32M in Q3 2016. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

  • TIAA CREF Investment Management held 85,036 shares of Lexicon Pharmaceuticals worth $473K as of Q1 2019.
  • TIAA CREF Investment Management sold 52,231 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $317K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2620 holding.
  • TIAA CREF Investment Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Lexicon Pharmaceuticals position peaked at $5.32M in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.